Insider Selling: GRAIL (NASDAQ:GRAL) CEO Sells 123,502 Shares of Stock

Key Points

• GRAIL CEO Robert Ragusa sold 123,502 shares on April 8 at an average price of $49.92 for proceeds of $6,165,219.84, reducing his stake by 19.23% to 518,582 shares (worth about $25.9M).
• Market and financial snapshot: GRAL traded at $47.56 (down $3.22) with a market cap of ~$1.95B, a 1‑year range of $21.80–$118.84, negative PE (-4.25) and high beta (4.62); the company reported Q4 EPS of -$2.44 (beating estimates) and $43.6M revenue, while analysts have a "Moderate Buy" consensus and an average target of $72.83.

GRAIL, Inc. (NASDAQ:GRAL - Get Free Report) CEO Robert Ragusa sold 123,502 shares of the business's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the sale, the chief executive officer owned 518,582 shares in the company, valued at $25,887,613.44. This represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

GRAIL Price Performance

GRAL traded down $3.22 during midday trading on Thursday, reaching $47.56. 901,496 shares of the company's stock were exchanged, compared to its average volume of 1,270,402. GRAIL, Inc. has a 1-year low of $21.80 and a 1-year high of $118.84. The stock has a market capitalization of $1.95 billion, a PE ratio of -4.25 and a beta of 4.62. The business's 50-day moving average price is $66.02 and its 200 day moving average price is $79.75.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. The firm had revenue of $43.60 million during the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative return on equity of 17.11% and a negative net margin of 277.46%. As a group, analysts expect that GRAIL, Inc. will post -15.15 EPS for the current fiscal year.

Analyst Ratings Changes

GRAL has been the topic of a number of analyst reports. Canaccord Genuity Group reduced their target price on GRAIL from $105.00 to $80.00 and set a "buy" rating on the stock in a research report on Friday, February 20th. Robert W. Baird set a $82.00 price objective on shares of GRAIL in a research note on Friday, February 20th. Morgan Stanley cut their price objective on shares of GRAIL from $110.00 to $60.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 24th. TD Cowen raised shares of GRAIL from a "hold" rating to a "buy" rating and set a $65.00 target price on the stock in a research report on Wednesday, March 18th. Finally, Guggenheim lowered their target price on shares of GRAIL from $130.00 to $75.00 and set a "buy" rating for the company in a report on Monday, March 30th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $72.83.

Institutional Investors Weigh In On GRAIL

Several institutional investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its position in shares of GRAIL by 17.7% in the first quarter. Royal Bank of Canada now owns 88,082 shares of the company's stock worth $2,250,000 after buying an additional 13,264 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of GRAIL by 28.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company's stock valued at $76,000 after buying an additional 623 shares during the period. NewEdge Advisors LLC lifted its position in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock worth $45,000 after acquiring an additional 1,401 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in GRAIL by 37.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 92,465 shares of the company's stock worth $2,362,000 after acquiring an additional 25,177 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in GRAIL by 115.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 79,544 shares of the company's stock worth $4,090,000 after acquiring an additional 42,675 shares during the period.

About GRAIL

GRAIL, Inc NASDAQ: GRAL is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company's platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.